Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial

Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3 milestone outside of lung cancer. Akeso said ivonescimab met a primary endpoint ...